Randomised clinical trials investigating the PD-1/PD-L1 blockade, either as monotherapy or in combination with chemotherapy or targeted agents, in patients with metastatic BC, demonstrated objective responses and median OS ranging from 0% to 52% and from 8.1 to 17.2 months, respectively [89,92,94]. The gene discussed is CD274; the disease is breast cancer.